Johnson & Johnson (JNJ) Tops Q4 EPS by 1c, Offers FY20 Guidance
(Updated - January 22, 2020 6:33 AM EST)
Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.88, $0.01 better than the analyst estimate of $1.87. Revenue for the quarter came in at $20.7 billion versus the consensus estimate of $20.77 billion.
GUIDANCE:
Johnson & Johnson sees FY2020 EPS of $8.95-$9.10, versus the consensus of $9.10. Johnson & Johnson sees FY2020 revenue of $85.4-86.2 billion, versus the consensus of $85.48 billion.
January 2020 | |
($ in Billions, except EPS) | |
Adjusted Operational Sales1,2 Change vs. Prior Year | 5.0% - 6.0% |
Operational Sales2 Change vs. Prior Year | $85.8 to $86.6 4.5% - 5.5% |
Estimated Reported Sales3 Change vs. Prior Year | $85.4 to $86.2 4.0% - 5.0% |
Adjusted Operational EPS (Diluted)2,4 Change vs. Prior Year | $9.00 to $9.15 3.7% - 5.4% |
Adjusted EPS (Diluted)3,4 Change vs. Prior Year | $8.95 to $9.10 3.1% - 4.8% |
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.